NetworkNewsBreaks

FridayFeb 14, 2020 1:02 pm

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Featured in ROTH Equity Research Report

Moleculin Biotech (NASDAQ: MBRX) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Yesterday, MBRX announced the successful conclusion to its open label, single arm U.S. Phase 1 liposomal annamycin trial, having achieved a highly favorable safety profile in relapsed or refractory AML, as well as clear signs of efficacy in two of the six patients. MBRX also provided an interim update on its European Phase 1 annamycin trial, replicating the clean safety profile, even at higher doses than in the U.S. trial, as well as a similar fraction of patients showing…

Continue Reading

FridayFeb 14, 2020 12:59 pm

NetworkNewsBreaks – Spartan Motors, Inc. (NASDAQ: SPAR) Featured in ROTH Equity Research Report

Spartan Motors (NASDAQ: SPAR) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Earlier today, SPAR announced the sale of its Emergency Response (ER) segment to REV Group (REVG-NC) for $55mn in cash. We see the sale as a positive development as management can focus time and resources on the more profitable and faster growing FVS and SCV businesses. Shares jumped ~6% on the news; however, we believe the stock continues to move higher as we see the transaction driving an improvement in margins and ROIC, while strengthening the balance sheet. Reiterate…

Continue Reading

FridayFeb 14, 2020 12:31 pm

NetworkNewsBreaks – Myomo, Inc. (NYSE American: MYO) Secures $15M in Underwritten Public Offering

Myomo (NYSE American: MYO), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, has closed an underwritten public offering of 2,143,000 common stock shares or common stock equivalents (including pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 2,143,000 common stock shares. Myomo secured gross proceeds of approximately $15.0 million, with each share of common stock (or pre-funded warrant in lieu thereof) sold together with one investor warrant to purchase one share of common…

Continue Reading

FridayFeb 14, 2020 11:36 am

NetworkNewsBreaks – Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) to Present at Live Investor Conference & Webinar on February 20

Siyata Mobile (TSX.V: SIM) (OTCQX: SYATF) will present for the upcoming Virtual Investor Conference, the leading proprietary investor conference series where company executives share vision and answer audience questions at VirtualInvestorConferences.com. According to the update, the event opens at 9:15 AM ET on Thursday, February 20, and Siyata Mobile’s live webcast is scheduled to begin at 9:30 AM ET. Investors are encouraged to pre-register (http://nnw.fm/1ZmYY) and run the online system check to expedite participation and receive event updates. There are no fees to log-in, attend the live presentations or ask questions. To view the full press release, visit http://nnw.fm/h4uLE About…

Continue Reading

FridayFeb 14, 2020 11:32 am

NetworkNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Launches “Smart Immersive Physical Education Classes” in Fujian and Guangdong, China

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of augmented reality interactive entertainment games, toys and educational materials in China, today announced the launch of “Smart Immersive Physical Education Classes,” an innovative smart product that integrates education with technology. According to the update, the first iteration of the product is already in use in preschools in China's Fujian and Guangdong provinces. “We believe our Smart Immersive Physical Education Classes represent the next step towards effective gamification of dynamic education for children between the ages of three and six years old,” Blue Hat CEO Xiaodong Chen said…

Continue Reading

FridayFeb 14, 2020 10:34 am

NetworkNewsBreaks – Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) Reports Q3 Fiscal Year 2020 Financial Results, Provides Corporate Update

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today released its financial results for the three and nine months ended December 31, 2019. According to the update, the company’s unaudited condensed interim consolidated financial statements as well as its management's discussion and analysis (“MD&A”) for Q3 2020 are available under the company's profile SEDAR at www.SEDAR.com and on the company's website. “In the third quarter, we continued pursuing our goal to become the leading venture capital firm building the cannabis industry of tomorrow,” Canopy Rivers President and CEO Narbé Alexandrian said in the news release.…

Continue Reading

FridayFeb 14, 2020 10:23 am

NetworkNewsBreaks – Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Posts Q2 2020 Results and Outlook; Enters Exclusive Agreement with Humble & Fume Inc.

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) on Thursday announced its financial and operating results for the three and six months ended December 31, 2019, as well as an update on its strategy and outlook. In addition, Thursday marked the announcement of Supreme Cannabis’ entry into a landmark sales agreement with Humble & Fume Inc. ("humble+fume"), one of North America's leading distributors of cannabis accessories. Under the agreement, humble+fume will act as the exclusive sales agent for Supreme Cannabis' recreational products across Canada, creating the only sales force in Canada able to offer a complete solution of cannabis…

Continue Reading

FridayFeb 14, 2020 10:13 am

NetworkNewsBreaks – ChineseInvestors.com Inc. (CIIX) CEO Discusses Potential Health Benefits of CBD on MoneyTV with Donald Baillargeon

ChineseInvestors.com (OTCQB: CIIX) was featured on this week’s episode of MoneyTV with Donald Baillargeon. The internationally syndicated program, viewed in over 200 million households and more than 75 countries, covers money-focused topics and features in-depth interviews with CEOs and executives that offer insights into various companies and their operations and future outlooks. This week’s program featured CIIX CEO Warren Wang as he discussed the company’s CBD Biotech division and his personal experience using CBD oil. “Based upon my experience with CBD oil, it can help people improve their health condition,” CIIX CEO Warren Wang stated in the interview. “Three years…

Continue Reading

FridayFeb 14, 2020 9:25 am

NetworkNewsBreaks – SinglePoint, Inc. (SING) CEO Discusses Hemp Cigarette Brand on MoneyTV with Donald Baillargeon

SinglePoint (OTCQB: SING) was featured on this week’s episode of MoneyTV with Donald Baillargeon. The internationally syndicated program covers money-focused topics, featuring various companies and in-depth interviews with CEOs and executives that offer insights into operations and future outlooks. MoneyTV is viewed in over 200 million households in more than 75 countries. Among other highlights from this week’s program, SinglePoint CEO Greg Lambrecht discussed the company’s ideal position to profit from its hemp cigarette brand as the price of hemp flower has decreased. “The price of hemp flower has really gone down. There's been so many farmers that have started…

Continue Reading

FridayFeb 14, 2020 9:00 am

NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Inks Exclusive License Agreement with University of Pittsburgh for Diabetes Gene Therapy

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and other serious diseases, recently announced its entry into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect approximately 30.3 million people in the U.S., or 9% of the U.S. population. According to the update, Genprex’s licensed diabetes gene therapy technology is designed to reprogram alpha cells in the pancreas into beta-like cells, restoring their function, thereby replenishing insulin levels. “We are…

Continue Reading